Effect of ranolazine on ventricular repolarization in class III antiarrhythmic drug-treated rabbits

Heart Rhythm

Volumn 9, Issue 12, 2012, Pages 2051-2058

  Frommeyer, Gerrit ^a   Kaiser, Dennis ^a   Uphaus, Timo ^a   Kaese, Sven ^a   Osada, Nani ^b   Rajamani, Sridharan ^c   Belardinelli, Luiz ^c   Breithardt, Günter ^a   Eckardt, Lars ^a   Milberg, Peter ^a  

^a Department of Cardiovascular Medicine   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c Gilead Sciences ^*  (United States)

Author keywords

Amiodarone; Dispersion of repolarization; Dronedarone; Postrepolarization refractoriness; Proarrhythmia; Ranolazine; Repolarization reserve

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DRONEDARONE; POTASSIUM ION; RANOLAZINE; SOTALOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; EXPERIMENTAL MODEL; EXPERIMENTAL RABBIT; EXTRACELLULAR SPACE; FEMALE; HEART MUSCLE POTENTIAL; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; NONHUMAN; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; REFRACTORY PERIOD; THERAPY EFFECT;

ACETANILIDES; ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HEART VENTRICLES; PIPERAZINES; RABBITS; TACHYCARDIA, VENTRICULAR;

EID: 84870413566     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2012.08.029     Document Type: Article

References (41)

1. A.K. Dhalla, W.Q. Wang, J. Dow et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion Am J Physiol Heart Circ Physiol 297 2009 H1923 H1929
2. T.J. Bunch, S. Mahapatra, D. Murdock et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks Pacing Clin Electrophysiol 34 2011 1600 1606
3. A.J. Moss, W. Zareba, K.Q. Schwarz, S. Rosero, S. McNitt, J.L. Robinson Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome J Cardiovasc Electrophysiol 19 2008 1289 1293
4. A. Burashnikov, J.M. Di Diego, A.C. Zygmunt, L. Belardinelli, C. Antzelevitch Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine Circulation 116 2007 1449 1457
5. S. Sicouri, A. Glass, L. Belardinelli, C. Antzelevitch Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations Heart Rhythm 5 2008 1019 1026
6. K. Kumar, B.D. Nearing, M. Carvas et al. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart J Cardiovasc Electrophysiol 20 2009 796 802
7. R.H. Miles, R. Passman, D.K. Murdock Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting Am J Cardiol 108 2011 673 676
8. D.K. Murdock, M. Kersten, J. Kaliebe, G. Larrain The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation Indian Pacing Electrophysiol J 9 2009 260 267
9. M.J. Koren, M.R. Crager, M. Sweeney Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE) J Am Coll Cardiol 49 2007 1027 1034
10. S.R. Wilson, B.M. Scirica, E. Braunwald et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial J Am Coll Cardiol 53 2009 1510 1516
11. A. Burashnikov, S. Sicouri, J.M. Di Diego, L. Belardinelli, C. Antzelevitch Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation J Am Coll Cardiol 56 2010 1216 1224
12. S. Sicouri, A. Burashnikov, L. Belardinelli, C. Antzelevitch Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria Circ Arrhythm Electrophysiol 3 2010 88 95
13. S. Fredj, K.J. Sampson, H. Liu, R.S. Kass Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action Br J Pharmacol 148 2006 16 24
14. C. Antzelevitch, L. Belardinelli, A.C. Zygmunt et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties Circulation 110 2004 904 910
15. B.N. Singh, S.J. Connolly, H.J. Crijns et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter N Engl J Med 357 2007 987 999
16. + current J Cardiovasc Pharmacol 51 2008 581 589
17. B.R. Chaitman Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions Circulation 113 2006 2462 2472
18. D.M. Roden Taking the "idio" out of "idiosyncratic": predicting torsades de pointes Pacing Clin Electrophysiol 21 1998 1029 1034
19. P. Milberg, L. Eckardt, H.J. Bruns et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes J Pharmacol Exp Ther 303 2002 218 225
20. P. Milberg, S. Ramtin, G. Mönnig et al. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block J Cardiovasc Pharmacol 44 2004 278 286
21. P. Milberg, G. Frommeyer, T. Uphaus et al. Electrophysiologic profile of dronedarone on the ventricular level: beneficial effect on postrepolarization refractoriness in the presence of rapid phase 3 repolarization J Cardiovasc Pharmacol 59 2012 92 100
22. G. Frommeyer, P. Milberg, P. Witte et al. A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure Eur J Heart Fail 13 2011 1060 1069
23. P. Kirchhof, H. Degen, M.R. Franz et al. Amiodarone-induced postrepolarization refractoriness suppresses induction of ventricular fibrillation J Pharmacol Exp Ther 305 2003 257 263
24. R. Candinas, J. Frielingsdorf, H.R. Ha, T. Carrel, M. Turina, F. Follath Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure Eur J Clin Pharmacol 53 1998 331 336
25. W. Sun, J.S. Sarma, B.N. Singh Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone J Cardiovasc Pharmacol 39 2002 677 684
26. N. Freemantle, C. Lafuente-Lafuente, S. Mitchell, L. Eckert, M. Reynolds Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation Europace 13 2011 329 345
27. P.G. Jorens, P.A. van den Heuvel, R.E. Ranquin, F.A. van den Branden, G.A. Parizel Amiodarone induced torsades de pointe: report of three cases and review of literature Acta Cardiol 44 1989 411 421
28. C. Antzelevitch, A. Burashnikov, S. Sicouri, L. Belardinelli Electrophysiologic basis for the antiarrhythmic actions of ranolazine Heart Rhythm 8 2011 1281 1290
29. P. Milberg, R. Tegelkamp, N. Osada et al. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome J Cardiovasc Electrophysiol 18 2007 658 664
30. H.V. Huikuri, S. Yli-Mayry Frequency dependent effects of d-sotalol and amiodarone on the action potential duration of the human right ventricle Pacing Clin Electrophysiol 15 1992 2103 2107
31. Na in guinea pig ventricular myocytes J Cardiovasc Pharmacol 44 2004 192 199
32. L. Wu, S. Rajamani, H. Li, C.T. January, J.C. Shryock, L. Belardinelli Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart Am J Physiol Heart Circ Physiol 297 2009 H1048 H1057
33. J.M. van Opstal, M. Schoenmakers, S.C. Verduyn et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome Circulation 104 2001 2722 2727
34. S.C. Verduyn, M.A. Vos, J. van der Zande, F.F. van der Hulst, H.J. Wellens Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: reversal by magnesium Cardiovasc Res 34 1997 453 463
35. M. Zabel, S.H. Hohnloser, S. Behrens, R.L. Woosley, M.R. Franz Differential effects of d-sotalol, quinidine, and amiodarone on dispersion of ventricular repolarization in the isolated rabbit heart J Cardiovasc Electrophysiol 8 1997 1239 1245
36. L.M. Hondeghem, L. Carlsson, G. Duker Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic Circulation 103 2001 2004 2013
37. M.B. Thomsen, S.C. Verduyn, M. Stengl et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs Circulation 110 2004 2453 2459
38. P. Milberg, G. Frommeyer, A. Kleideiter et al. Antiarrhythmic effects of free polyunsaturated fatty acids in an experimental model of LQT2 and LQT3 due to suppression of early afterdepolarizations and reduction of spatial and temporal dispersion of repolarization Heart Rhythm 8 2011 1492 1500
39. G. Antoons, A. Oros, J.D. Beekman et al. Late Na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model J Am Coll Cardiol 55 2010 801 809
40. M.B. Thomsen, P.G. Volders, J.D. Beekman, J. Matz, M.A. Vos Beat-to-beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes J Am Coll Cardiol 48 2006 1268 1276
41. P.J. Schwartz, S.G. Priori, C. Spazzolini et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias Circulation 103 2001 89 95